Summary
The product Semaglutide 5mg, manufactured by EOQ Remedies, underwent independent testing to verify its authenticity and potency. The sample, identified by batch number VTS744, was submitted by EOQ Remedies and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Semaglutide, with a concentration of 6.10 mg, exceeding the labeled claim of 5 mg by 22%.
The testing process began on 6 November 2024, with the sample received on 15 November 2024, and analysis completed on 18 November 2024. While the results confirm accurate dosing with a slight overdose, scrutiny of manufacturer-submitted samples is essential to ensure reliability. Manufacturers may select specific batches that meet high-quality standards, raising questions about product consistency across the broader market. Independent third-party testing remains critical to validate these findings comprehensively. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: EOQ Remedies
- Product Name: Semaglutide 5mg
- Active Ingredient: Semaglutide
- Batch Number: VTS744
- Expiration Date: Not provided
- Delivery Method: Lyophilized (Freeze-Dried) Powder
Sample Acquisition and Testing
- Task Number: #52843
- Testing Ordered: 6 November 2024
- Sample Received: 15 November 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: EOQ Remedies (Manufacturer)
- Analysis Paid For By: EOQ Remedies (Manufacturer)
Testing Results
- Specification: 5 mg (as stated on the label)
- Measured Concentration: 6.10 mg
- Accuracy: 122% (22% above the label claim)
- Purity: 98.861%
Verification Details
- Verification URL: https://janoshik.com/tests/52843_GPM3DZB6S6Y8
Evaluation of Manufacturer-Submitted Testing
This analysis highlights the accuracy of the tested product but warrants careful evaluation due to its submission and funding by EOQ Remedies. Manufacturers often select optimal batches for testing, which may not fully represent the consistency of products available to consumers. While Janoshik Analytical is recognized for its transparency and rigorous testing protocols, these findings would benefit from independent validation through third-party testing across multiple batches.
Conclusion
The analysis confirms that Semaglutide 5mg is slightly overdosed, with a measured concentration of 6.10 mg. This result reflects strong quality control for this batch but underscores the importance of additional testing to ensure consistent dosing across the product line. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding peptide products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
